Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) has issued an update.
Sawai Group Holdings Co., Ltd. announced that the Intellectual Property High Court of Japan ruled against its subsidiary, Sawai Pharmaceutical Co., Ltd., in a patent infringement lawsuit concerning Nalfurafine Hydrochloride OD Tablets. The court’s decision requires Sawai Pharmaceutical to pay damages amounting to over 14 billion yen. The company is assessing the financial impact and plans to appeal the decision, indicating potential implications for its financial statements and legal strategy.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. operates in the pharmaceutical industry, primarily focusing on the manufacturing and marketing of generic drugs. Its subsidiary, Sawai Pharmaceutical Co., Ltd., is involved in the production of Nalfurafine Hydrochloride OD Tablets, among other products.
Average Trading Volume: 593,310
Technical Sentiment Signal: Sell
Current Market Cap: Yen187.8B
Find detailed analytics on 4887 stock on TipRanks’ Stock Analysis page.